European Penny Stocks: Raisio And Two More Promising Picks

As European markets navigate the tug-of-war between improving growth prospects and inflation concerns, investors are increasingly exploring diverse opportunities. Penny stocks, though an older term, refer to smaller or less-established companies that can offer significant value. By focusing on those with strong financials and clear growth potential, investors might uncover promising opportunities within this segment.

Let's uncover some gems from our specialized screener.

Raisio (HLSE:RAIVV)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Raisio plc, with a market cap of €361.01 million, produces and sells food and food ingredients in Finland, the United Kingdom, and internationally through its subsidiaries.

Operations: The company generates revenue primarily from Finland (€110.9 million) and the United Kingdom (€49.7 million).

Market Cap: €361.01M

Raisio plc, with a market cap of €361.01 million, operates debt-free and trades below its estimated fair value by 38.5%. The company's short-term assets significantly exceed both its short and long-term liabilities, indicating strong financial health. However, recent earnings have shown a decline in net income compared to the previous year despite slight sales growth. Raisio's management team has undergone changes with new CEO Elli Siltala assuming leadership in September 2026, bringing extensive industry experience but raising potential concerns about stability due to recent executive turnover. The dividend yield of 6.59% is not well covered by earnings or free cash flow.

• Dive into the specifics of Raisio here with our thorough balance sheet health report.
• Understand Raisio's earnings outlook by examining our growth report.

Glycorex Transplantation (NGM:GTAB B)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Glycorex Transplantation AB (publ) is a medical technology company that focuses on researching, developing, manufacturing, marketing, and selling products related to organ transplantation, with a market cap of SEK95.02 million.

Operations: The company generates revenue of SEK34.57 million from its organ transplantation segment.

Market Cap: SEK95.02M

Glycorex Transplantation AB, with a market cap of SEK95.02 million, remains unprofitable but maintains a positive free cash flow and sufficient cash runway for over three years. Despite volatile share prices and declining revenue—SEK17.7 million for the first half of 2026—the company is debt-free and has secured new distribution agreements in Brazil, Malaysia, and Argentina. These deals could open significant market opportunities in regions performing thousands of kidney transplants annually. However, the management team lacks extensive experience, as indicated by an average tenure below two years.

• Click here to discover the nuances of Glycorex Transplantation with our detailed analytical financial health report.
• Understand Glycorex Transplantation's track record by examining our performance history report.

OssDsign (OM:OSSD)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: OssDsign AB (publ) is a company that designs, manufactures, and sells implants and material technology for bone regeneration in the United States, with a market cap of SEK392.72 million.

Operations: The company generates its revenue of SEK163.80 million from its medical products segment.

Market Cap: SEK392.72M

OssDsign AB, with a market cap of SEK392.72 million, is currently unprofitable but has managed to reduce its losses over the past five years by 13.6% annually. Despite being dropped from the S&P Global BMI Index in September 2026, the company remains debt-free and has sufficient cash runway for more than three years if free cash flow continues to grow at historical rates. Its short-term assets of SEK202.9 million comfortably cover both short-term and long-term liabilities, while revenue is forecast to grow by 28.34% per year, suggesting potential for future expansion in its medical products segment.

• Jump into the full analysis health report here for a deeper understanding of OssDsign.
• Evaluate OssDsign's prospects by accessing our earnings growth report.

Next Steps

• Click here to access our complete index of 312 European Penny Stocks.
• Looking For Alternative Opportunities? AI is about to change healthcare. These 133 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com